{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:21:33Z","timestamp":1785813693210,"version":"3.56.0"},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T00:00:00Z","timestamp":1334534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A major challenge in the assessment of medicines, treatment options, etc., is to establish a framework for the comparison of risks and benefits of many different types and magnitudes, a framework that at the same time allows a clear distinction between the roles played by the statistical analyses of data and by judgements based on personal experience and expertise. The purpose of this study was to demonstrate how clinical data can be weighted, scored and presented by the use of an eight\u2010step data\u2010driven benefit\u2013risk assessment method, where two genetic profiles are compared. Our aim was to present a comprehensive approach that is simple to apply, allows direct comparison of different types of risks and benefits, quantifies the clinical relevance of data and is tailored for the comparison of different options. We analysed a cohort of 302 patients with colorectal cancer treated with 5\u2010Fluorouracil (5\u2010<jats:styled-content style=\"fixed-case\">FU<\/jats:styled-content>). Endpoints were cure rate, survival rate, time\u2010to\u2010death (<jats:styled-content style=\"fixed-case\">TTD<\/jats:styled-content>), time\u2010to\u2010relapse (<jats:styled-content style=\"fixed-case\">TTR<\/jats:styled-content>) and main adverse drug reactions. Multifactor dimensionality reduction (<jats:styled-content style=\"fixed-case\">MDR<\/jats:styled-content>) was used to identify genetic interaction profiles associated with outcome. We have been able to demonstrate that a specific <jats:styled-content style=\"fixed-case\">MDR<\/jats:styled-content>\u2010derived combination (the <jats:styled-content style=\"fixed-case\">MDR<\/jats:styled-content>\u20101 group) of dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms is associated with increased and clinically significant difference for cure and survival rates, <jats:styled-content style=\"fixed-case\">TTD<\/jats:styled-content> and probably also for <jats:styled-content style=\"fixed-case\">TTR<\/jats:styled-content>, which are seen as the most important endpoints. An inferior profile was observed for severe myocardial ischaemia. A probably inferior profile was seen for severe arthralgia\/myalgia and severe infections. A clear superior profile was seen for severe mucositis\/stomatitis. The proposed approach offers comprehensive, data\u2010driven assessment that can facilitate decision processes, for example, in a clinical setting. It employs descriptive statistical methods to highlight the clinically relevant differences between options.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2012.00885.x","type":"journal-article","created":{"date-parts":[[2012,3,26]],"date-time":"2012-03-26T23:24:16Z","timestamp":1332804256000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Data\u2010Driven Assessment of the Association of Polymorphisms in 5\u2010Fluorouracil Metabolism Genes with Outcome in Adjuvant Treatment of Colorectal Cancer"],"prefix":"10.1111","volume":"111","author":[{"given":"Sinan B.","family":"Sarac","sequence":"first","affiliation":[{"name":"Novo Nordisk A\/S Bagsv\u00e6rd Denmark"},{"name":"Department of Physics Technical University of Denmark Lyngby Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S Bagsv\u00e6rd Denmark"},{"name":"Department of Physics Technical University of Denmark Lyngby Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoaib","family":"Afzal","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry Herlev Hospital Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Thirstrup","sequence":"additional","affiliation":[{"name":"Danish Medicines Agency Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren A.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Oncology Herlev Hospital Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Colding\u2010J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S Bagsv\u00e6rd Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik E.","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology Rigshospitalet Copenhagen Denmark"},{"name":"Department of Clinical Pharmacology Bispebjerg Hospital Copenhagen Denmark"},{"name":"Faculty of Health Sciences University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Mosekilde","sequence":"additional","affiliation":[{"name":"Department of Physics Technical University of Denmark Lyngby Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,16]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"The Council for International Organizations of Medical Sciences (CIOMS).Working CIOMS group IV \u2013 benefit\u2010risk balance for marketed drugs: evaluating safety signals [online]. Available from URL:http:\/\/www.cioms.ch\/publications\/g4-benefit-risk.pdf. 1998."},{"key":"e_1_2_6_3_1","unstructured":"US Food and Drug Administration (FDA).The future of drug safety \u2013 promoting and protecting the health of the public [online]. Available from URL:http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM171627.pdf. 2007."},{"key":"e_1_2_6_4_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).Report of the CHMP working group on benefit\u2010risk assessment models and methods. EMEA\/CHMP\/15404\/2007 [online]. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2010\/01\/WC500069634.pdf. CHMP; 2008."},{"key":"e_1_2_6_5_1","unstructured":"Measuring Benefit and Balancing Risk: Strategies for the benefit\u2010risk assessment of new medicines in a risk\u2010averse environment Washington DC US: 19\u201320 June 2008. Report of the Workshop organised by the CMR International Institute for Regulatory Science. Available from URL:http:\/\/www.cmr.org. 2008."},{"key":"e_1_2_6_6_1","unstructured":"Strategies for Communicating Benefit\u2010Risk to Decision Makers: Explaining Methods Findings and Conclusions Through a Common Approach Washington DC US: 17\u201319 June 2009. Report of the Workshop organised by the CMR International Institute for Regulatory Science. Available from URL:http:\/\/www.cmr.org\/workshops. 2009."},{"key":"e_1_2_6_7_1","unstructured":"Benefit\u2010risk methodology project \u2013 work package 2 report: applicability of current tools and processes for regulatory benefit\u2010risk assessment. EMA\/549682\/2010[online]. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/10\/WC500097750.pdf. European Medicines Agency (EMA); 2010."},{"key":"e_1_2_6_8_1","unstructured":"Benefit risk methodology project \u2013 work package 1: description of the current practice of benefit\u2010risk assessment for centralised procedure products in the EU regulatory network. EMA\/213482\/2010 [online]. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/04\/WC500089603.pdf. 2010."},{"key":"e_1_2_6_9_1","volume-title":"978\u20100\u2010470\u201006085\u20108 (H\/B) Benefit\u2010Risk Appraisal of Medicines \u2013 A Systematic Approach to Decision\u2010Making","author":"Mussen F","year":"2009"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.277"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.290"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61462-6"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2003.0225"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/009286150704100514","article-title":"How to improve complex drug development? A critical review of FDA advisory meetings","volume":"41","author":"Boudes PF","year":"2007","journal-title":"Drug Inf J"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1162\/biot.2009.4.1.44"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742\u20107843.2012.00871.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.83"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00612a022"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0021-9258(17)42421-5","article-title":"Fluoropyrimidine\u2010mediated changes in small nuclear RNA","volume":"261","author":"Armstrong RD","year":"1986","journal-title":"J Biol Chem"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1016\/S0021-9258(18)68949-5","article-title":"5\u2010Fluorouracil substitution alters pre\u2010mRNA splicing in vitro","volume":"263","author":"Doong SL","year":"1988","journal-title":"J Biol Chem"},{"key":"e_1_2_6_21_1","first-page":"144","article-title":"Biochemical determinants of responsiveness to 5\u2010fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice","volume":"41","author":"Houghton JA","year":"1981","journal-title":"Cancer Res"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)00216-R"},{"key":"e_1_2_6_23_1","first-page":"643","article-title":"Thymidylate synthase level as the main predictive parameter for sensitivity to 5\u2010fluorouracil, but not for folate\u2010based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines","volume":"5","author":"van Triest B","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700393"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601523"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh015"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.08.164"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.039"},{"key":"e_1_2_6_29_1","first-page":"4116","article-title":"Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5\u2010fluorouracil","volume":"9","author":"Kornmann M","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"e_1_2_6_30_1","first-page":"3700","article-title":"Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5\u2010fluorouracil\u2010based oral adjuvant chemotherapy in colorectal cancer","volume":"9","author":"Tsuji T","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.064"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000175598.42141.59"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.5253"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20553"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000230412.89973.c0"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f4aea6"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm599"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp046"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605052"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.59"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21412"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0304"},{"key":"e_1_2_6_43_1","volume-title":"Value Focused Thinking \u2013 A Path to Creative Decisionmaking","author":"Keeney RL","year":"1992"},{"key":"e_1_2_6_44_1","first-page":"285","volume-title":"Sums of Random Variables. Introduction to Probability","author":"Grinstead CM","year":"1997"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-8-270"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2012.00885.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2012.00885.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:21:59Z","timestamp":1698787319000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2012.00885.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,16]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1742-7843.2012.00885.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2012.00885.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,16]]},"assertion":[{"value":"2011-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-04-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}